Chemoinformaics analysis of 1,2,6,8-TETRAHYDROXYXANTHEN-9-ONE
| Molecular Weight | 260.201 | nRot | 0 |
| Heavy Atom Molecular Weight | 252.137 | nRig | 13 |
| Exact Molecular Weight | 260.032 | nRing | 3 |
| Solubility: LogS | -3.33 | nHRing | 1 |
| Solubility: LogP | 4.961 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 27 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 19 | No. of Aromatic Carbocycles | 2 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 8 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 13 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 14 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 16 |
| nHA | 6 | APOL | 31.8563 |
| nHD | 4 | BPOL | 10.6297 |
| QED | 0.689 |
| Synth | 2.41 |
| Natural Product Likeliness | 1.462 |
| NR-PPAR-gamma | 0.807 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.458 |
| Pgp-sub | 0.001 |
| HIA | 0.006 |
| CACO-2 | -4.882 |
| MDCK | 0.0000229 |
| BBB | 0.055 |
| PPB | 0.994436 |
| VDSS | 1.565 |
| FU | 0.00921156 |
| CYP1A2-inh | 0.971 |
| CYP1A2-sub | 0.331 |
| CYP2c19-inh | 0.959 |
| CYP2c19-sub | 0.063 |
| CYP2c9-inh | 0.793 |
| CYP2c9-sub | 0.96 |
| CYP2d6-inh | 0.967 |
| CYP2d6-sub | 0.907 |
| CYP3a4-inh | 0.568 |
| CYP3a4-sub | 0.252 |
| CL | 17.658 |
| T12 | 0.858 |
| hERG | 0.031 |
| Ames | 0.147 |
| ROA | 0.116 |
| SkinSen | 0.955 |
| Carcinogencity | 0.067 |
| EI | 0.945 |
| Respiratory | 0.129 |
| NR-Aromatase | 0.89 |
| Antiviral | Yes |
| Prediction | 0.693464 |